LAUSR

The expression and roles of FLOT2, especially for its underlying mechanism, in gliomas have been rarely revealed. In this study, upregulations of both FLOT2 and EphA2 in gliomas tissues were validated by immunohistochemistry (IHC) staining and Western blot. FLOT2 silencing notably inhibited the growth and invasion of gliomas cells. Simultaneously, FLOT2 depletion suppressed Akt and NF-κB activities, induced apoptosis, cell cycle arrest, and epithelial-mesenchymal transition (EMT) inhibition, demonstrated by expression alterations of key proteins of the above processes. Mechanistically, FLOT2 could maintain EphA2 stability viainteraction, and restoration of EphA2 could remarkably release the suppressive effects on gliomas cells induced by FLOT2 knockdown. Lastly, FLOT2 and EphA2, whose protein and mRNA levels are both positively correlated in gliomas, shows significant association with clinical characteristics like Ki67 intensity, p53 expression, and tumor stage in patients with gliomas. In conclusion, our results reveal the upregulation, oncogenic roles of FLOT2, and the corresponding underlying mechanism in gliomas, highlighting that the FLOT2-EphA2 axis is served as a promising therapeutic target for gliomas.